EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC-ND 4.0

Postoperative vedolizumab in Crohn's disease: interpreting persistence, endoscopic recurrence, and treatment strategy

Leyi Xu, Ting Ye

Digestive and Liver Disease · 2026-11

DOI: 10.1016/j.dld.2026.10.030 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Digestive and Liver Disease, 2026-11. Verfasst von Leyi Xu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, the Affiliated Hospital of Southwest Medical University, Sichuan, China. Electronic address: xuleyi582@gmail.com. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Laboratory Medicine, the Affiliated Hospital of Southwest Medical University, Sichuan, China. Electronic address: xuleyi582@gmail.com.
  • Department of Laboratory Medicine, the Affiliated Hospital of Southwest Medical University, Sichuan, China. Electronic address: yeting1103@163.com.

Zitieren

APA

Xu, L., & Ye, T. (2026). Postoperative vedolizumab in Crohn's disease: interpreting persistence, endoscopic recurrence, and treatment strategy. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2026.10.030

Vancouver

Xu L, Ye T. Postoperative vedolizumab in Crohn's disease: interpreting persistence, endoscopic recurrence, and treatment strategy. Digestive and Liver Disease. 2026. doi:10.1016/j.dld.2026.10.030

BibTeX
@article{Xu2026,
  author = {Xu, Leyi and Ye, Ting},
  title = {Postoperative vedolizumab in Crohn's disease: interpreting persistence, endoscopic recurrence, and treatment strategy},
  journal = {Digestive and Liver Disease},
  year = {2026},
  doi = {10.1016/j.dld.2026.10.030}
}
Kostenlos starten →